Physician profile
Ali Usmani
NPI 1013968817
$3,759.17
in general payments reported to CMS, 2019-2025
28 companies · $712 in 2025
The $712 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $905 · 2020: $598 · 2021: $263 · 2022: $638 · 2023: $195 · 2024: $448 · 2025: $712.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,266 · Education: $89.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,266.03 |
| Education | $89.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $522.10 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $330.18 | 2020-2025 | Camzyos |
| Abbott Laboratories | $287.76 | 2022-2023 | Cardiomems |
| Reflow Medical INC | $249.09 | 2023-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $238.55 | 2019-2024 | Lifevest |
| Amgen INC. | $230.04 | 2019-2020 | |
| Astrazeneca Pharmaceuticals Lp | $200.19 | 2019-2022 | |
| Boston Scientific Corporation | $175.85 | 2024-2025 | Watchman Flx, Cds - Mct/Cem Monitoring, Eluvia |
| Janssen Pharmaceuticals, INC | $165.94 | 2021-2024 | Xarelto |
| Sanofi-Aventis U.S. LLC | $155.29 | 2019 | |
| Astellas Pharma US INC | $154.99 | 2020 | |
| Janssen Scientific Affairs, LLC | $124.99 | 2022 | |
| Kestra Medical Technology Services, INC. | $123.52 | 2024 | Assure Wcd |
| Penumbra, INC. | $120.00 | 2022 | |
| Esperion Therapeutics, INC. | $115.75 | 2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bard Peripheral Vascular, INC. | $113.22 | 2019-2021 | |
| Pfizer INC. | $98.28 | 2019-2025 | |
| Actelion Pharmaceuticals US, INC. | $89.00 | 2025 | Opsumit, Uptravi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $57.10 | 2024-2025 | Jardiance |
| Novo Nordisk INC | $33.10 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Merck Sharp & Dohme LLC | $28.02 | 2024 | Winrevair |
| Cook Medical LLC | $27.87 | 2025 | Zilver Ptx |
| Abiomed | $26.06 | 2025 | |
| Kiniksa Pharmaceuticals International, Plc | $19.93 | 2024 | Arcalyst |
| Scpharmaceuticals INC. | $19.79 | 2024 | |
| Heartflow, INC. | $19.55 | 2025 | |
| United Therapeutics Corporation | $17.64 | 2025 | Orenitram |
| Lexicon Pharmaceuticals, INC. | $15.37 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ali Usmani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.